160 likes | 298 Views
Prior Studies Combining Lytic GP IIb/IIIa Inhibitors. Angiographic TrialsHigher rates of early TIMI 3 flowReduced time to restoration of flowImproved myocardial reperfusionLess reocclusion / re-elevation of STLarge Clinical TrialsNo difference in mortalityLess reinfarction, recurrent ischem
E N D